

DOCTOR'S ORDER SHEET -PHARMACY - STELARA (ustekinumab)

Place patient identification sticker here

Allergi	es:		
		Height Weight I ****UNAPPROVED ABBREVIATIONS****	кg
QD, QOD, MgSO ₄ , MSO ₄ , MS, IU, U or -u, ug, Use of a Trailing Zero (X.0mg), Lack of a Leading Zero(Xmg)			
DATE	TIME	ORDERS	NURSE SIGNATURE
		Assign to Outpatient status	
		PREMEDICATIONS:	
		0.9% sodium chloride (NS) IV at KVO	
		☐ No pre-medications necessary	
		methylprednisolone sodium succinate injectionmg IV x 1 dose 30 mins prior to infusion	
		diphenhydraminemg IV x1 dose 30 mins prior to infusion	
		diphenhydraminemg PO x 1 dose 30 mins prior to infusion	
		acetaminophen 650mg PO x 1 dose 30 mins prior to infusion	
		MEDICATION:	
		Stelara (ustekinumab) in 0.9% NS 250ml IV infusion with a low-protein bidning 0.2 micron in-line filter	
		☐INDUCTION INFUSION:	
		Dose: ☐ 260mg (<55kg) ☐ 390mg (55-85kg) ☐ 520mg (>85kg)	
		Route: Intravenous	
		Frequency: Once	
		Infusion Duration: 60 minutes	
		If infusion-related reaction:	
		1.) STOP infusion immediately;	
		2.) Increase 0.9% sodium chloride (NS) infusion to wide open rate;	
		3.) Administer PRN medications per infusion reaction medication ordered;	
		4.) Call Max Cart;	
		5.) Notify MD	1
		INFUSION REACTION MEDICATIONS:	
		albuterol inhalation nebulizer solution 2.5mg/0.5ml (concentrated solution)	
		(Note: dilute with 2.5ml of NS for an albuterol 2.5mg/3ml dose)	
		Dose: 2.5mg via nebulizer as needed for shortness of breath/wheezing	
		diphenhydrAMINE injectable	
		Dose: 25mg IV x 1 dose for urticaria, pruritus, shortness of breath. May repeat in 15 minutes if	
		symptoms not resolved EPINEPHrine 1mg/ml (1:1000) injectable	
		Dose: 0.3mg IM x1 dose as needed for anaphylaxis	
		methylPREDNISolone sodium succinate 125mg injection	
		Dose: 125mg IV x1 dose as needed for hypersensitivity	
		NURSING ORDERS:	
		 Initial Dose only: Verify PPD or quanti-FERON-TB assay for latent TB results are negative for TB 	
		Ensure CBC has been drawn within the last 8 weeks, if not, instruct patient to receive lab draw	
		immediately. Notify provider if patient is more than 12 weeks overdue for labs	
		Ensure all immunizations are current before initiating therapy	
		 Ensure patient has not received MMR vaccine (measles, mumps, rubella vaccine), Rotavirus vaccine, 	
		Smallpox vaccine, YF-Vax (Yellow Fever) vaccine, MMRV (measles, mumps, rubella, and chickenpox)	
		vaccine, or chickenpox vaccine within 3 weeks of initiation (Document in Meditech Intervention). Live	
		vaccines should not be given concurrently or within 3 months of discontinuation of ocrelizumab.	
		 Do not administer ocrelizumab and notify provider if patient has a temperature >100°F, complains of 	
		symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection	
		Monitor patient for signs/symptoms of hypersensitivity during infusion and for 60 mins post-infusion Discourting	
DECEDE:		Discontinue IV line when therapy complete and patient stabilized INSERALL POINT PEN FAX TO BHARMACY	
REFERENCES: Stelara Prescribing Information USE BALL POINT PEN FAX TO PHARMACY			
Qualifi	ed Me	dical Provider signature Date Time	
Saumi	CG IVIC	aloan Frontier Duto Tillo	

Developed/Approved: 11/19